NICE says no to Xalkori; appeal is 'pointless' says Pfizer
This article was originally published in Scrip
Executive Summary
Despite the offer of a price discount, Pfizer has failed to convince NICE, the health technology appraisal institute for England and Wales, to recommend its lung cancer drug Xalkori (crizotinib). NICE says the drug is not cost-effective and has doubts over its overall survival benefits.